Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year Low – Here’s What Happened
Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) shares reached a new 52-week low during trading on Monday . The ...
Alumis Inc.’s ESK-001: A Promising TYK2 Inhibitor with Blockbuster Potential
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report) and keeping the price target at ...
Business Insider4d
Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating
Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target of $25.00. Discover the latest stocks recommended by ...
Yahoo Finance1d
Kazia Therapeutics Limited (KZIA)
Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting ...
Yahoo Finance1d
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...
Investing3d
CytoMed Therapeutics Ltd (GDTC)
SINGAPORE - CytoMed Therapeutics Limited (NASDAQ: GDTC), a biopharmaceutical company specializing in cell-based therapies for cancer treatment, has announced the commencement of a... ByInvesting ...
Investing6d
Century Therapeutics Inc (IPSC)
On Tuesday, H.C. Wainwright adjusted its stock price target for Century Therapeutics (NASDAQ:IPSC) shares, reducing it to $5 from the previous $9, while maintaining a Buy rating ...